CFCM / EVIDENCE
Evidence
Primary sources. Clear boundaries. Independent analysis.
CFCM analysis
Editorial interpretations of primary evidence. These articles are not themselves primary research.
Flow Cytometry as a Cell-Therapy Release Assay
Flow can contribute to product characterisation and release testing. Identity, viability and potency must remain distinct claims.
CFCM ANALYSISClinical Flow AI Under the EU AI Act
The regulatory question begins with intended purpose and the product's role. An accuracy score cannot determine the legal classification.
CFCM ANALYSISSynthetic Controls, Spectral MRD and Reproducibility
Reference materials and clinical spectral MRD are advancing in parallel. Their convergence needs evidence at the assay level.
CFCM ANALYSISThe 40-Colour Race May Be Ending
The useful question is how much reliable biological information a workflow delivers. Colour count alone cannot answer it.
CFCM ANALYSISHas Clinical Spectral Flow Cytometry Finally Arrived?
Clinical spectral cytometry is moving from technical possibility toward MRD and other validated clinical workflows.
CFCM ANALYSISDeep Learning for Mature B-Cell Neoplasms Reaches Clinical-Scale Data
What clinical-scale deep learning studies mean for automated analysis of mature B-cell neoplasms by flow cytometry.
Read the source in context
Source types remain distinct: guidelines, standards, original research, reviews, consensus, regulatory material, manufacturer documentation and abstracts or preprints.